4 resultados para Espinosa y Dávalos, Pedro 1793-1866.
em BORIS: Bern Open Repository and Information System - Berna - Suiça
Resumo:
Background The effectiveness of durable polymer drug-eluting stents comes at the expense of delayed arterial healing and subsequent late adverse events such as stent thrombosis (ST). We report the 4 year follow-up of an assessment of biodegradable polymer-based drug-eluting stents, which aim to improve safety by avoiding the persistent inflammatory stimulus of durable polymers. Methods We did a multicentre, assessor-masked, non-inferiority trial. Between Nov 27, 2006, and May 18, 2007, patients aged 18 years or older with coronary artery disease were randomly allocated with a computer-generated sequence to receive either biodegradable polymer biolimus-eluting stents (BES) or durable polymer sirolimus-eluting stents (SES; 1:1 ratio). The primary endpoint was a composite of cardiac death, myocardial infarction, or clinically-indicated target vessel revascularisation (TVR); patients were followed-up for 4 years. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00389220. Findings 1707 patients with 2472 lesions were randomly allocated to receive either biodegradable polymer BES (857 patients, 1257 lesions) or durable polymer SES (850 patients, 1215 lesions). At 4 years, biodegradable polymer BES were non-inferior to durable polymer SES for the primary endpoint: 160 (187%) patients versus 192 (226%) patients (rate ratios [RR] 081, 95% CI 066100, p for non-inferiority <00001, p for superiority=0050). The RR of definite ST was 062 (035108, p=009), which was largely attributable to a lower risk of very late definite ST between years 1 and 4 in the BES group than in the SES group (RR 020, 95% CI 006067, p=0004). Conversely, the RR of definite ST during the first year was 099 (051195; p=098) and the test for interaction between RR of definite ST and time was positive (pinteraction=0017). We recorded an interaction with time for events associated with ST but not for other events. For primary endpoint events associated with ST, the RR was 086 (041180) during the first year and 017 (004078) during subsequent years (pinteraction=0049). Interpretation Biodegradable polymer BES are non-inferior to durable polymer SES and, by reducing the risk of cardiac events associated with very late ST, might improve long-term clinical outcomes for up to 4 years compared with durable polymer SES. Funding Biosensors Europe SA, Switzerland.
Resumo:
OBJECTIVES This study sought to report the final 5 years follow-up of the landmark LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) trial. BACKGROUND The LEADERS trial is the first randomized study to evaluate biodegradable polymer-based drug-eluting stents (DES) against durable polymer DES. METHODS The LEADERS trial was a 10-center, assessor-blind, noninferiority, "all-comers" trial (N=1,707). All patients were centrally randomized to treatment with either biodegradable polymer biolimus-eluting stents (BES) (n= 857) or durable polymer sirolimus-eluting stents (SES) (n= 850). The primary endpoint was a composite of cardiac death, myocardial infarction (MI), or clinically indicated target vessel revascularization within 9 months. Secondary endpoints included extending the primary endpoint to 5 years and stent thrombosis (ST) (Academic Research Consortium definition). Analysis was by intention to treat. RESULTS At 5 years, the BES was noninferior to SES for the primary endpoint (186 [22.3%] vs. 216 [26.1%], rate ratio [RR]: 0.83 [95% confidence interval (CI): 0.68 to 1.02], p for noninferiority <0.0001, pfor superiority= 0.069). The BES was associated with a significant reduction in the more comprehensive patient-orientated composite endpoint of all-cause death, any MI, and all-cause revascularization (297 [35.1%] vs. 339 [40.4%], RR: 0.84 [95% CI: 0.71 to 0.98], p for superiority= 0.023). A significant reduction in very late definite ST from 1 to 5 years was evident with the BES (n= 5 [0.7%] vs. n= 19 [2.5%], RR: 0.26 [95% CI: 0.10 to 0.68], p= 0.003), corresponding to a significant reduction in ST-associated clinical events (primary endpoint) over the same time period (n= 3 of 749 vs. n= 14 of 738, RR: 0.20 [95% CI: 0.06 to 0.71], p= 0.005). CONCLUSIONS The safety benefit of the biodegradable polymer BES, compared with the durable polymer SES, was related to a significant reduction in very late ST (>1 year) and associated composite clinical outcomes. (Limus Eluted From A Durable Versus ERodable Stent Coating [LEADERS] trial; NCT00389220).
